An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications about 58% were on their treatment plan for less than 12 weeks, falling short of a key benchmark in the weight-loss treatment timeline
Worldwide agencies, such as the European Medicines Agency or Japans PMDA, have their own standards, and all must be satisfied before retatrutide can be marketed in those nations
Based on conversations with Lamya Kamal, a Dubai-based family medicine specialist and Zeenat Naseeb Abdul Wahid, Consultant Endocrinology, Medcare Hospital Sharjah, Hala Zakaria, Researcher at Zone Health and Nas Al Jafari, a Dubai-based functional medicinal specialist at DNA Health Clinic, we break it down
may have important implications on the accessibility and adherence of these drugs in the future, [because] currently all agents approved for weight loss are injections. The results showed frequent adverse events during the trials, ranging from 80% to 97% for GLP-1 receptor agonists and coagonists and 63% to 100% for placebo